Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Surg Clin North Am ; 81(1): 169-83, ix, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11218163

ABSTRACT

Anorectal disease affects many patients with Crohn's disease. Clinical manifestations vary from asymptomatic skin tags to severe, debilitating perineal destruction and sepsis. Surgical management needs to be conservative and must focus on draining septic sites, preserving sphincter function, and palliating symptoms. Medical management has had some success in improving symptoms, but as yet, it has not been able to ameliorate most perianal complaints quickly and enduringly. Many new and exciting treatment modalities are being investigated with the hope that more effective approaches to these complex and difficult problems can be realized.


Subject(s)
Anus Diseases/surgery , Crohn Disease/surgery , Rectal Diseases/surgery , Abscess/etiology , Anus Diseases/complications , Anus Diseases/diagnosis , Anus Diseases/epidemiology , Anus Neoplasms/etiology , Crohn Disease/complications , Crohn Disease/diagnosis , Crohn Disease/epidemiology , Fecal Incontinence/etiology , Female , Hemorrhoids/etiology , Humans , Intestinal Fistula/etiology , Male , Patient Selection , Prevalence , Rectal Diseases/complications , Rectal Diseases/diagnosis , Rectal Diseases/epidemiology , Rectal Neoplasms/etiology , Rectovaginal Fistula/etiology
2.
Otolaryngol Head Neck Surg ; 123(5): 539-42, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11077336

ABSTRACT

OBJECTIVE: This investigation is a prospective, randomized, blinded study seeking to evaluate the efficacy of hyperbaric oxygen (HBO) therapy in improving the survival of the reattached auricular composite graft. STUDY DESIGN: Twenty New Zealand White rabbits were randomly assigned to control (10) and treatment (10) groups in a prospective fashion. After amputation and reattachment of measured segments of each ear, the treatment group received 14 HBO treatments for 10 days. The control group received only standard postoperative care. On postoperative day 18, the surviving composite grafts were measured, recorded, and statistically analyzed. RESULTS: The mean percentage of graft survival for the control group was 0.31% (range 0%-2.5%), and the mean for the group receiving HBO was 15.94% (range 0%-38%). A median test was used to evaluate this difference, which was found to be statistically significant (P = 0057). CONCLUSION: Our study appears to indicate a possible survival benefit for the composite grafts in those rabbits that received HBO treatments. We believe that there are several significant difficulties with the rabbit as a model for this study, but we are encouraged at this point that a limited measurable benefit was observed. Further investigations with HBO appear to be warranted at this time.


Subject(s)
Ear, External/transplantation , Graft Survival , Hyperbaric Oxygenation , Animals , Models, Animal , Pilot Projects , Prospective Studies , Rabbits
3.
Am J Otolaryngol ; 21(3): 190-4, 2000.
Article in English | MEDLINE | ID: mdl-10834554

ABSTRACT

Penetrating injuries of the visceral compartment of the neck are uncommon but potentially life threatening. A retrospective review of patients who sustained penetrating trauma to the laryngotracheal complex was conducted at the Level I trauma center of the University of Louisville Hospital in Kentucky. Sixteen patients were identified and their records reviewed for type of injuries, treatment, complications, and 1-year follow-up. The majority of patients were men who sustained injuries that were violent in nature. Zone II of the anterior neck was the most commonly injured area, with the trachea (69%), esophagus (38%), and larynx (31 %) the most commonly injured structures. Although 31% underwent angiograms, only 13% showed vascular injuries. Eighty-one percent of the patients had injuries involving more than 1 major structure of the neck. Neck exploration was performed in 81% of the patients and tracheotomies in 75% as well as repair of the trachea (50%), larynx (31%), and esophagus (38%). There is significant mortality associated with these injuries (13% in our study), and many of the patients have long-term sequelae such as dysphagia, hoarseness, and prolonged tracheotomy.


Subject(s)
Carotid Artery Injuries/complications , Jugular Veins/injuries , Laryngeal Nerve Injuries , Neck Injuries/complications , Neck Injuries/diagnosis , Wounds, Penetrating/complications , Wounds, Penetrating/diagnosis , Adolescent , Adult , Aged , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neck Injuries/surgery , Retrospective Studies , Wounds, Penetrating/surgery
4.
JPEN J Parenter Enteral Nutr ; 23(5 Suppl): S20-4, 1999.
Article in English | MEDLINE | ID: mdl-10483888

ABSTRACT

The etiology and pathogenesis of inflammatory bowel disease (IBD) remains an area under intense investigation. Cytokine secretion, which is important in the regulation of normal gastrointestinal immune responses, appears to be dysregulated in IBD. In Crohn's disease, there appears to be an excessive T(H)1 T-cell response to an antigenic stimulus, leading to increased levels of proinflammatory cytokines, such as interferon-gamma (IFN-gamma), interleukin (IL)-12, IL-1, IL-6, and tumor necrosis factor-alpha (TNF-alpha). In ulcerative colitis, a T(H)2 T-cell response appears to be the pathological process responsible for the inflammatory disease. New and innovative therapeutic strategies targeting cytokines, such as TNF-alpha, are producing some promising results in animal and human studies. As more is learned about the complex cytokine interactions in IBD, more effective treatments will undoubtedly ensue.


Subject(s)
Cytokines/physiology , Immune System/physiology , Inflammatory Bowel Diseases/etiology , Animals , Cytokines/blood , Humans , Inflammatory Bowel Diseases/immunology , Inflammatory Bowel Diseases/therapy , Interleukins/immunology , T-Lymphocytes, Helper-Inducer/immunology , T-Lymphocytes, Helper-Inducer/physiology
5.
Biochem J ; 342 ( Pt 2): 345-52, 1999 Sep 01.
Article in English | MEDLINE | ID: mdl-10455021

ABSTRACT

Mutations in the glucokinase (GK) gene cause type-2 maturity-onset diabetes of the young type 2 (MODY-2) and GK-linked hyperinsulinaemia (GK-HI). Recombinant adenoviruses expressing the human wild-type islet GK or one of four mutant forms of GK, (the MODY-2 mutants E70K, E300K and V203A and the GK-HI mutant V455M) were transduced into glucose-responsive insulin-secreting beta-HC9 cells and tested functionally in order to initiate the first analysis in vivo of recombinant wild-type and mutant human islet GK. Kinetic analysis of wild-type human GK showed that the glucose S(0. 5) and Hill coefficient were similar to previously published data in vitro (S(0.5) is the glucose level at the half-maximal rate). E70K had half the glucose affinity of wild-type, but similar enzyme activity. V203A demonstrated decreased catalytic activity and an 8-fold increase in glucose S(0.5) when compared with wild-type human islet GK. E300K had a glucose S(0.5) similar to wild-type but a 10-fold reduction in enzyme activity. E300K mRNA levels were comparable with wild-type GK mRNA levels, but Western-blot analyses demonstrated markedly reduced levels of immunologically detectable protein, consistent with an instability mutation. V455M was just as active as wild-type GK, but with a markedly reduced S(0.5). The effects of the different GK mutants on glucose-stimulated insulin release support the kinetic and expression data. These experiments show the utility of a combined genetic, biochemical and cell-biological approach to the quantification of functional and structural changes of human GK that result from MODY-2 and GK-HI mutations.


Subject(s)
Diabetes Mellitus/enzymology , Diabetes Mellitus/genetics , Glucokinase/genetics , Insulin/blood , Point Mutation , Adenoviridae/genetics , Animals , Cell Line , Gene Expression Regulation, Enzymologic , Glucokinase/metabolism , Glucose/pharmacology , Humans , In Vitro Techniques , Insulin/metabolism , Insulin Secretion , Islets of Langerhans/drug effects , Islets of Langerhans/enzymology , Islets of Langerhans/metabolism , Kinetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Transfection
7.
J Surg Res ; 72(2): 155-61, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9356237

ABSTRACT

Recombinant adenovirus accomplishes highly efficient gene transfer in vivo. Adenoviral vectors would be more attractive vehicles for gene therapy if transgene expression was inducible and restricted to the target tissue. In these studies, we hypothesized that selective transgene expression of a recombinant adenovirus could be accomplished by using a tissue-specific promoter of transcription. A replication-defective adenoviral vector was engineered to express the lacZ marker gene under control of the murine pancreatic amylase promoter. Expression of this vector occurred exclusively in the pancreas in neonatal and adult mice, while a similar vector with a constitutive promoter accomplished transgene expression in several organs. Within the adenoviral construct, the amylase promoter retained its ability to be induced by dexamethasone and insulin. This model will serve as a paradigm for selective and inducible adenoviral transgene expression.


Subject(s)
Adenoviridae/genetics , Amylases/genetics , Genetic Vectors , Pancreas/metabolism , Promoter Regions, Genetic/genetics , Transcription, Genetic/genetics , Adenoviridae/ultrastructure , Amylases/analysis , Animals , Base Sequence , Blotting, Southern , DNA/analysis , DNA/chemistry , DNA/genetics , Dexamethasone/pharmacology , Gene Expression Regulation, Viral , Genetic Therapy , HeLa Cells , Humans , Insulin/pharmacology , Lac Operon/genetics , Mice , Mice, Inbred C57BL , Models, Genetic , Pancreas/enzymology , Recombination, Genetic
8.
Pancreas ; 15(3): 236-45, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9336786

ABSTRACT

Gene transfer technology may provide a novel approach to treatment for pancreatic diseases. Recombinant adenovirus achieves efficient gene transfer in vivo. In this study, a murine model of adenoviral-mediated pancreatic gene transfer was developed, and the factors responsible for adenoviral elimination were investigated. Three days after direct pancreatic injection of a replication-defective adenovirus containing the lacZ transgene, a high proportion (76.8 +/- 6.7%) of pancreatic cells expressed beta-galactosidase, the gene product. Gene expression was absent by 28 days posttransduction. In immunodeficient mice, beta-galactosidase expression persisted with 20.0 +/- 6.0% of pancreatic cells staining positive 60 days after viral transduction. To test whether early viral proteins are the antigenic components responsible for the potent antiviral immune response, normal mice were injected with different adenoviral vectors containing early gene deletions. Vectors containing deletions in early region 2 or 4 expressed beta-galactosidase at 28 days. Presently available adenoviral vectors engineered to avoid this response offer minimal improvements in transgene duration. Further vector modifications or alternative strategies are needed to achieve stable pancreatic adenoviral transgene expression.


Subject(s)
Adenoviridae/genetics , Adenovirus Early Proteins/genetics , Gene Transfer Techniques , Genes, Viral , Immunity , Pancreas/metabolism , Adenovirus E2 Proteins/genetics , Adenovirus E4 Proteins/genetics , Animals , Female , Genetic Vectors , Immunologic Deficiency Syndromes/genetics , Leukocytes , Mice , Mice, Inbred C57BL , Mice, Nude , Pancreas/cytology , Recombinant Proteins , beta-Galactosidase/genetics
9.
Hum Gene Ther ; 8(6): 739-46, 1997 Apr 10.
Article in English | MEDLINE | ID: mdl-9113513

ABSTRACT

Pancreatic adenoviral gene transfer can be achieved with high efficiency; however, questions concerning tissue injury from this commonly used vector have not been addressed. In these experiments, the effects of adenoviral gene transfer on pancreatic exocrine function were evaluated. Direct pancreatic injection with an adenoviral vector containing the Escherichia coli beta-galactosidase (beta-Gal; lacZ) transgene (H5.010CBlacZ) resulted in a high level of transgene expression (64 +/- 6% of pancreatic cells expressed beta-Gal) at 3 days following infection. However, amylase levels in four of five different subcellular pancreatic fractions were significantly decreased at this time point. Direct pancreatic injection with either saline or psoralen/UV-inactivated adenovirus did not have this effect, whereas both transduction with an adenoviral vector containing a different transgene and transduction with a homologous transgene resulted in decreased pancreatic amylase. The decrease in subcellular amylase levels persisted at 7 days post-transduction, and then returned to baseline at 21 days post-transduction. There was associated histologic damage (increased edema, inflammation, cell destruction, and vacuolization) at 3 and 7 days post-transduction, which resolved by 21 days. In summary, adenoviral transduction of the pancreas results in increased viral transgene expression and a uniform decrease in host amylase production throughout the pancreas. The normalization of amylase levels and histology suggest that organ recovery occurs. Gene transfer technology as a novel strategy for pancreatic diseases such as diabetes, pancreatitis, and cystic fibrosis is feasible but will benefit from continued approaches to limit toxicity.


Subject(s)
Adenoviridae , Gene Transfer Techniques , Pancreas/metabolism , Amylases/blood , Amylases/metabolism , Animals , Female , Gene Transfer Techniques/adverse effects , Genetic Vectors , Humans , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Pancreas/pathology , Pancreatitis/enzymology , Transgenes , beta-Galactosidase/genetics
10.
J Pediatr Surg ; 32(2): 373-7, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9044157

ABSTRACT

PURPOSE: The authors sought to assess the feasibility of in vivo gene transfer to the small intestine using recombinant adenovirus in neonatal and adult mice. METHODS: H5.010CMVlacZ is a replication-defective, E1-deleted human type 5 adenovirus, which contains the lacZ gene under the control of a cytomegalovirus promoter and enhancer. The lacZ gene was used as a marker because its gene product, beta-galactosidase, is readily detected by X-gal histochemistry. Sixty neonatal (3 to 5 days old) and 45 adult (6 to 8 weeks old) C57BL/6 mice were investigated. Intestinal gene transfer was attempted with H5.010CMVlacZ by intraperitoneal (i.p.), intraluminal (IL), and intramural (i.m.) injection. Based on prior studies, the optimal dose of H5.010CMVlacZ was 1 x 10(8) plaque forming units (pfu/mL). Control animals received saline injections. Gene transfer on repeat administration of adenovirus has been shown to be prevented by neutralizing antibody. To determine if neonatal inoculation induced a humoral immune response, neonates (n = 5) that received i.p. injections were rechallenged with intravenous H5.010CMV alkphos, a similar adenoviral construct containing the alkaline phosphatase marker gene. Serum samples were analyzed by Western blot to detect the presence of adenoviral-specific antibody. RESULTS: Gene transfer to neonatal small intestine was successful by IL gastric (n = 8/10), IL jejunal (n = 9/10) and i.p. (n = 10/10) routes 2 days after injection. Macroscopic staining was present in 90% of standardized 2-cm small bowel segments. Transgene expression was identified in intestinal smooth muscle, serosa, and epithelium. Gene transfer to the adult small intestine was successful by IL jejunal (n = 4/5), i.m. (n = 5/5), and i.p. (n = 1/5) injection of adenoviruslacZ with focal staining (< 5% of 2-cm segments) in epithelium including crypts, muscle, and serosa. Three weeks after i.p. H5.010CMVlacZ in neonates, intravenous injection with H5.010CMValkphos resulted in hepatic transgene expression (n = 4/5) that was indistinguishable from a primary intravenous inoculation; persistent, lacZ expression was not detectable in the liver or intestine (n = 0/5). Western blot analysis detected adenoviral-specific antibodies after adult IM but not after neonatal i.p. injection. Furthermore, 3 weeks after neonatal i.p. injection repeat administration by the i.m. route was successful (n = 4/ 4). CONCLUSION: Gene transfer to neonatal and adult small intestine is feasible using recombinant adenovirus and is more efficient in neonates as indicated by increased surface area of marker gene expression, effectiveness of intraperitoneal delivery, and the ability to readminister recombinant adenovirus.


Subject(s)
Adenoviruses, Human , Gene Transfer Techniques , Genetic Vectors , Intestine, Small , Age Factors , Animals , Animals, Newborn , DNA, Recombinant , Gene Expression , Lac Operon , Mice , Mice, Inbred C57BL , Transgenes
11.
J Pediatr Surg ; 32(12): 1695-703, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9434001

ABSTRACT

BACKGROUND/PURPOSE: Clinical application of gene therapy for patients who have inflammatory bowel disease or short bowel syndrome will require the development of new strategies to improve the efficiency of small intestinal gene transfer. Previously, the authors developed a method for adenoviral-mediated small intestinal gene transfer in vivo in neonatal and adult mice. The present study evaluates the hypothesis that the integrins alpha(v)beta3 and alpha(v)beta5, the secondary receptors for adenoviral internalization, play a facilitative role in neonatal murine adenoviral-mediated small intestinal gene transfer. METHODS: Immunohistochemical techniques identified the integrin alpha(v)beta3 and the integrin subcomponents alpha(v), beta3, and beta5 in neonatal and adult small intestine. The effects of integrin receptor antagonists on transgene expression was also studied in our neonatal model of adenoviral-mediated small intestinal gene transfer in vivo. RESULTS: Gene transfer was significantly decreased by the addition of integrin receptor antagonists versus control peptide. Integrin alpha(v)beta3 and integrin subcomponent alpha(v), beta3, and beta5 are expressed in neonatal and adult small intestine. Integrin antagonists administered simultaneously blocked efficient adenoviral-mediated neonatal small intestinal gene transfer in vivo compared with control peptide. CONCLUSION: Strategies to upregulate integrin expression may improve adenoviral-mediated small intestinal gene transfer.


Subject(s)
Adenoviruses, Human , Antigens, CD/metabolism , Gene Transfer Techniques , Intestine, Small/metabolism , Animals , Animals, Newborn , Genetic Vectors , Immunohistochemistry , In Situ Hybridization , Integrin alphaV , Integrins/antagonists & inhibitors , Integrins/metabolism , Intestine, Small/ultrastructure , Mice , Mice, Inbred C57BL , Receptors, Vitronectin/antagonists & inhibitors , Receptors, Vitronectin/metabolism , Transgenes , Up-Regulation
12.
Hum Gene Ther ; 8(18): 2207-16, 1997 Dec 10.
Article in English | MEDLINE | ID: mdl-9449374

ABSTRACT

The pancreas is an ideal organ for adenoviral gene therapy because of the high level of gene transfer that can be achieved and because of the many diseases that can potentially be treated using this technology. In this report, we characterize the immune response to direct pancreatic injection of adenovirus and we overcome some of the limitations it imposes by using immunosuppression. Direct injection of recombinant adenovirus into the pancreas leads to the production of neutralizing antibodies and to sensitized splenocytes which engage in increased cytotoxic, lymphoproliferative, and cytokine release activity when reexposed to adenovirus. Transgene expression is transient and the vector cannot be readministered. Deletion of CD4+ T helper cells improves expression over time (40% of pancreatic cells express transgene at day 28 vs. 5% in controls), and allows the vector to be readministered in the pancreas, albeit, inefficiently, when compared to naive animals. Similarly, blockade of CD40 ligand, which preserves the CD4+ T helper cell population, also improves expression over time (30% of pancreatic cells express transgene at day 28), and allows the vector to be readministered. With both approaches, neutralizing antibodies are decreased and the remaining splenocytes do not engage in activated immune responses. Thus, local delivery of the adenoviral vector induces a systemic response that prevents pancreatic readministration, even with direct injection. Blockade of CD40 ligand and T helper cell depletion are transient regimens that induce systemic immunosuppression. Until the development of newer strategies that selectively suppress adenoviral immune responses, these are viable alternatives for enhancement of pancreatic adenoviral delivery.


Subject(s)
Adenoviruses, Human/immunology , Gene Transfer Techniques , Genetic Vectors/immunology , Pancreas/immunology , Alkaline Phosphatase/biosynthesis , Alkaline Phosphatase/genetics , Animals , Antibodies/analysis , Antibodies, Viral/analysis , CD4-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/cytology , Cytokines/metabolism , Female , Flow Cytometry , Gene Expression , Mice , Mice, Inbred C57BL , Neutralization Tests , Spleen/cytology , T-Lymphocytes, Cytotoxic/immunology , Transgenes
13.
J Pediatr Surg ; 31(8): 1026-30; discussion 1030-1, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8863225

ABSTRACT

Thirty-eight children (2 months to 26 years of age) underwent esophageal replacement at our institution between 1962 and 1993. Twenty-four patients had esophageal atresia, with the replacement performed at a mean age of 17 months. The remaining patients (37%) had strictures and were older (mean, 7.4 years). Replacement procedures involved the right colon in 61% of cases and the transverse left colon in the others (39%). Sixty-three percent were placed substernally and 37% were done in transthoracic fashion. The average length of stay in the hospital was 34 days (range, 11 to 256 days.) Early complications (within 30 days) included cervical anastomotic leaks (11 patients; 29%) pneumonia (4), would infection (2), pneumothorax/hemothorax (3), wound dehiscence (1), prolonged ventilation (2), vocal cord paralysis (1), Horner's syndrome (1), pancreatitis (1), and perforated graft (1). Despite the incidence of early leaks, only two persisted long-term (more than 3 months). Other late complications included significant proximal strictures (5), and cologastric strictures developed in five patients. Seven cases were considered graft failures (18%), and all of these eventually require graft replacement. Additional problems included redundant graft requiring revision (4) and dumping syndrome (2). There were six cases of intestinal obstruction caused by adhesions. Four of these involved intrathoracic obstruction of the graft and two involved small bowel obstruction. There was only one death, which occurred late and was not related to the primary disease or procedure. Long-term follow-up data were available for 20 patients (53%). The follow-up period ranged from 1 to 33 years (mean, 12 years). Fourteen had excellent results after the initial interposition, being able to eat and function well without any further intervention. Seven patients (18%) have had poor results and 17 (45%) required additional procedures to obtain good functional results. In our experience, the colon continues to be a good option for esophageal replacement, but additional procedures frequently are necessary to optimize the functional outcome. Good results can be expected in the majority of cases, but late problems (ie, redundant colon and poor emptying) are not unusual, and careful follow-up is essential in the management of such patients.


Subject(s)
Colon/transplantation , Esophageal Atresia/surgery , Esophageal Stenosis/surgery , Adolescent , Adult , Child , Child, Preschool , Esophageal Stenosis/etiology , Female , Follow-Up Studies , Graft Rejection/etiology , Humans , Incidence , Infant , Length of Stay , Male , Postoperative Complications/etiology , Reoperation , Treatment Outcome
14.
Brain Res ; 479(2): 349-54, 1989 Feb 13.
Article in English | MEDLINE | ID: mdl-2924163

ABSTRACT

Microdialysis probes inserted into chronically implanted guide shafts allowed the collection of serotonin and 5-hydroxyindoleacetic acid (5-HIAA) from the lateral hypothalamus of rats during feeding behavior. After the collection of baseline samples, animals were offered a palatable diet that they could only see and smell for 60 min, then they were allowed access to the food for an hour. An additional three samples were collected after food was removed. Extracellular serotonin increased during the first half hour of access when the animals actually ate the food, and then returned to baseline level throughout the remainder of the test. 5-HIAA decreased gradually with no increase during feeding. These data suggest that eating a meal of palatable food causes a short-term increase in extracellular serotonin in the lateral hypothalamus. This increased serotonin may play a role in the control of lateral hypothalamic feeding and reward.


Subject(s)
Feeding Behavior/physiology , Hypothalamic Area, Lateral/metabolism , Serotonin/metabolism , Animals , Extracellular Space , Male , Rats , Rats, Inbred Strains , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...